The facts.

There aren’t many reliable stats about low grade serous and borderline ovarian cancer. That’s because there hasn’t been enough research. Until now.

1 in 78 people with ovaries will be diagnosed with ovarian cancer in their lifetime.

image description

1 in 10
diagnosed
with ovarian
cancer are
under 45.

image description

The majority of those with low grade serous and borderline serous ovarian cancer will experience a recurrence.

The chance of them entering remission from chemotherapy is less than 20%.

The average survival rate after a low grade serous ovarian cancer diagnosis is 9 years.

image description

The current treatment options for low grade serous and borderline ovarian cancer are based on lack of data.

There is no test for the early detection of ovarian cancer.

image description

70% of diagnoses don’t happen until the cancer reaches stage III or IV.

image description

Many don’t notice ovarian cancer symptoms until the disease is in advanced stages.

In most cases, a diagnosis cannot be reached until after surgery.

Most surgery is exploratory to see how much cancer there is and what kind.

image description

Most surgeries are done by a general surgeon, not an oncologist gynecologist surgeon, because there are so few.

image description

The majority of these surgeries result in the removal of one or both ovaries, causing immediate menopause — no matter the age.

Not okay.

Self-advocacy shouldn’t be the only way to survive ovarian cancer.

image description
image description

Medical gaslighting is the #2 cause of ovarian cancer-related deaths.

The #1 cause is cancer.

Most women with ovarian cancer don’t get diagnosed until it’s too late because doctors assume their symptoms are just “woman problems”.

In fact, one study published in Academic Emergency Medicine found that women who went to the emergency room with severe stomach pain had to wait for almost 33% longer than men with the same symptoms.

image description

45% of women surveyed didn’t think their healthcare providers took their pain seriously.

And that doesn’t even factor in race or gender identity. Women of color and trans women are statistically less likely to be taken seriously about their symptoms than cis white women.

Not okay.

Funding research and trials shouldn’t take longer than the studies, themselves.

image description
image description

Participating in a drug trial doubles life expectancy.

The patients need more drug trials.

Something needs to change.
So, we’re changing it.